Get in touch!
We're here to help - feel free to reach out with any questions, thoughts, or requests, and we’ll get back to you as soon as we can.

For decades, saw palmetto (Serenoa repens) has occupied a prominent yet debated position in hair wellness. While frequently marketed as a natural dihydrotestosterone (DHT) blocker, historical support relied heavily on small, open-label pilot trials or multi-ingredient formulations where isolating the active botanical contribution remained challenging.
Recent clinical findings published in the Journal of Cosmetic Dermatology provide gold-standard, peer-reviewed evidence for an isolated, standardised liposterolic extract. The 180-day randomised, double-blind, placebo-controlled trial (ClinicalTrials.gov identifier: NCT06920758) offers concrete data on hair density, terminal hair count, and safety profiles in adults experiencing self-perceived hair thinning.
The research evaluated a high-concentration, standardised liposterolic saw palmetto extract across both male and postmenopausal female cohorts over a six-month period. By comparing the intervention against a placebo control, researchers measured change in specific quantitative metrics rather than relying solely on subjective self-assessments.
Key endpoints recorded at the 180-day mark demonstrated clear statistical separation from placebo:
The underlying physiological mechanism identified in the research centres on dual inhibition of type I and type II 5-alpha reductase (5-AR) enzymes, alongside direct androgen receptor blocking at the cellular level. 5-alpha reductase converts circulating testosterone into dihydrotestosterone (DHT), a primary driver of androgenetic follicle miniaturisation.
By inhibiting both 5-AR isoenzymes, the high-concentration liposterolic extract reduces local DHT activity within the follicular microenvironment.
A critical outcome of the trial methodology is the distinction between standardised liposterolic extracts and unstandardised whole-berry powders. Raw botanical mass or generic berry powder does not correlate directly with bioavailable active constituents.
The trial utilised a specific standardised extract (SEREVELLE) rich in liposterolic fatty acids. Because active potency depends entirely on lipid concentration, results from this clinical trial cannot be generalised to raw berry powders or low-concentration herbal preparations.
This distinction between standardised extracts and generic formulations is particularly important when evaluating saw palmetto’s wider potential benefits. For a broader examination of the evidence, including hair thinning, prostate health, and urinary function, explore our guide to saw palmetto for hair growth and urinary support.
While these peer-reviewed findings establish statistically significant efficacy for standardised saw palmetto, context remains essential:
For individuals seeking clinically validated botanical strategies, the 180-day data confirms that standardised liposterolic saw palmetto extract provides measurable support for hair density and terminal count in both men and postmenopausal women.